Kai-li Liang

Dr. Kai-li Liang

Oncology, Johns Hopkins Medicine, Baltimore, Maryland, USA
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 April 2025 in Cancers
Verified
Journal Article
Open access
PDF file
Kai-li LiangKai-li Liang
Kai-li Liang
NANilofer Azad
Nilofer Azad
Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer-related mortality in the United States, with poor overall survival across all stages. Less than 20% of patients are eligible for curative surgical resection at diagnosis, and despite adjuvant chemotherapy, most will experience disease recurrence within two years. The incorporation of immune-based strategies in the adjuvant setting remains an area of intense investigation with unrealized promise. It offers the potential of providing durable disease control for micro-metastatic disease following curative intent surgery and enabling personalized treatments based on mutational neoantigen profiles derived from resected specimens. However, most of these attempts have failed to demonstrate significant clinical success, likely due to the immunosuppressive tumor microenvironment (TME) and individual genetic heterogeneity. Despite these challenges, immune-based strategies, such as therapeutic vaccines targeted towards neoantigens, have demonstrated promise via immune activation and induction of T-cell tumor infiltration. In this review, we will highlight the foundational lessons learned from previous clinical trials of adjuvant immunotherapy, discussing the knowledge gained from analyses of trials with disappointing results. In addition, we will discuss how these data have been incorporated to design new agents and study concepts that are proving to be exciting in more recent trials, such as shared antigen vaccines and combination therapy with immune-checkpoint inhibitors and chemotherapy. This review will evaluate novel approaches in ongoing and future clinical studies and provide insight into how these immune-based strategies might evolve to address the unique challenges for treatment of PDAC in the adjuvant setting.

17 June 2022 in Current Oncology
Verified
Journal Article
Open access
PDF file
Kai-li LiangKai-li Liang
Kai-li Liang
STSean Tackett
Sean Tackett
SMSamantha Myers
Samantha Myers
JBJulie R. Brahmer
Julie R. Brahmer
IBIlene S. Browner
Ilene S. Browner
JFJosephine L FEliciano
Josephine L FEliciano
Introduction: With the increasing use of immune checkpoint inhibitors (ICI) for cancer, there is a growing burden on the healthcare system to provide care for the toxicities associated with these agents. Herein, we aim to identify and describe the distribution of encounters seen in an urgent care setting for immune-related adverse events (irAEs) and the clinical outcomes from irAE management. Methods: Patient demographics, disease characteristics, and treatment data were collected retrospectively from encounters at an oncology Urgent Care Clinic (UCC) from a single tertiary center for upper aerodigestive malignancies from 1 July 2018 to 30 June 2019. Data were summarized using descriptive statistics with odds ratios for associations between patient features and hospitalization after UCC evaluation. Results: We identified 494 encounters from 289 individual patients over the study period. A history of ICI therapy was noted in 34% (n = 170/494) of encounters and 29 encounters (29/170, 17%) were confirmed and treated as irAEs. For those treated for irAEs, the majority (n = 19/29; 66%) were discharged home. Having an irAE was associated with an increased risk of hospitalization compared to non-irAEs (OR 5.66; 95% CI 2.15–14.89; p < 0.001). Conclusion: In this single institution experience, the majority of UCC encounters for confirmed irAEs were safely managed within the UCC. In ICI-treated patients, having an irAE was associated with an increased risk of hospitalization versus non-irAEs.

9 December 2023 in ESMO Open
Verified
Journal Article
Open access
Kai-li LiangKai-li Liang
Kai-li Liang
JFJ.L. Feliciano
J.L. Feliciano
KMK.A. Marrone
K.A. Marrone
JMJ.C. Murray
J.C. Murray
CHC.L. Hann
C.L. Hann
VLVincent K Lam
Vincent K Lam
Brain metastasis (BRM) is uncommon in gastroesophageal cancer. As such, clinicopathologic and molecular determinants of BRM and impact on clinical outcome remain incompletely understood. We retrospectively analyzed clinicopathologic data from advanced esophageal/gastroesophageal junction (E/GEJ) patients at Johns Hopkins from 2003 to 2021. We investigated the association between several clinical and molecular features and the occurrence of BRM, with particular focus on human epidermal growth factor receptor 2 (HER2) overexpression. Survival outcomes and time to BRM onset were also evaluated. We included 515 patients with advanced E/GEJ cancer. Tumors were 78.3% esophageal primary, 82.9% adenocarcinoma, 31.0% HER2 positive. Cumulative incidence of BRM in the overall cohort and within HER2+ subgroup was 13.8% and 24.3%, respectively. HER2 overexpression was associated with increased risk of BRM [odds ratio 2.45; 95% confidence interval (CI) 1.10-5.46]. On initial presentation with BRM, 50.7% had a solitary brain lesion and 11.3% were asymptomatic. HER2+ status was associated with longer median time to onset of BRM (14.0 versus 6.3 months, P < 0.01), improved median progression free survival on first-line systemic therapy (hazard ratio 0.35, 95% CI 0.16-0.80), and improved median overall survival (hazard ratio 0.20, 95% CI 0.08-0.54) in patients with BRM. HER2 overexpression identifies a gastroesophageal cancer molecular subtype that is significantly associated with increased risk of BRM, though with later onset of BRM and improved survival likely reflecting the impact of central nervous system-penetrant HER2-directed therapy. The prevalence of asymptomatic and solitary brain lesions suggests that brain surveillance for HER2+ patients warrants prospective investigation.

3 August 2023
Verified
Conference Paper
Closed access
YGYingxue Gao
Yingxue Gao
RFRuohan Feng
Ruohan Feng
LZLihua Zhuo
Lihua Zhuo
Kai-li LiangKai-li Liang
Kai-li Liang
WBWeijie Bao
Weijie Bao
XHXiaoQi Huang
XiaoQi Huang
The current study investigate functional network alterations in adolescent MDD using the clustering analysis. We found that adolescents with MDD showed decreased connectivity between the frontoparietal network (FPN) and other networks relative to HC. The global connectivity strength of FPN was negatively correlated with the punishment and academic pressure factors, and mediated the association between these two stressors and depression. Our findings suggest that punishment and academic pressure may contribute to the development of depression in adolescence through dysfunction of the FPN, which may promote future prevention of adolescent MDD.

3 August 2023
Verified
Conference Paper
Closed access
WBWeijie Bao
Weijie Bao
LCLingxiao Cao
Lingxiao Cao
RFRuohan Feng
Ruohan Feng
YGYingxue Gao
Yingxue Gao
HLHailong Li
Hailong Li
XHXiaoQi Huang
XiaoQi Huang
Evidence has emerged to suggest the important role of cortical gyrification morphology in adult major depressive disorder (MDD). However, little is known about how the altered cortical gyrification contribute to adolescent patients who is at a critical period of brain development. We address this gap by examining the difference of local gyrification index (LGI) between adolescent MDD patients and HCs. We found that MDD patients showed significant increased LGI in the left PCC and bilateral lingual gyrus, which characterize the neurobiological mechanisms of adolescent MDD and may be important to understand the developmental effect of this disorder.